A new trial will test whether blocking the IDH mutation can keep grade 3 brain tumors from coming back

Grade 3 IDH-mutant astrocytoma is a brain cancer that follows a cruel pattern. Surgery removes the visible tumor. Radiation and chemotherapy with temozolomide attack what remains. And then, in many patients, the cancer comes back - driven by the same genetic mutation that defined it from the start.

The mutations in the IDH1 or IDH2 genes produce an abnormal protein that fuels tumor growth. Temozolomide damages tumor cell DNA, but it doesn't specifically target the IDH pathway. A new phase III trial led by the Alliance for Clinical Trials in Oncology will test whether adding a drug that does - vorasidenib - can keep these tumors from recurring.

Vorasidenib enters the brain

Vorasidenib is an oral medication designed specifically to cross the blood-brain barrier and block the proteins produced by mutated IDH1 and IDH2 genes. The blood-brain barrier is a major obstacle for brain cancer drugs - many compounds that work against cancer cells in a dish or elsewhere in the body simply cannot reach tumors in the brain at therapeutic concentrations.

That vorasidenib is brain-penetrant and targeted to the specific mutation driving these tumors makes it a logical candidate to add to existing treatment. The question is whether combining it with temozolomide after radiation produces better outcomes than temozolomide alone.

Trial design

The study, designated Alliance A072301 and supported in part by a National Cancer Institute grant, will randomize participants into two groups. The standard arm receives radiation therapy followed by temozolomide plus placebo for one year, then placebo alone. The intervention arm receives radiation followed by temozolomide plus vorasidenib for one year, then vorasidenib alone.

All participants receive the same follow-up care, including regular MRI scans, blood tests, and clinical visits.

The primary outcome is progression-free survival - how long patients live without their tumor growing or returning. Researchers will also track overall survival, safety, and the side-effect profile of the combination. Ugonma Chukwueke, the Alliance study chair and a neuro-oncologist at Dana-Farber Cancer Institute, described the trial as addressing a long-standing unmet need. If successful, vorasidenib could become the first widely used IDH-targeted medicine added to standard care for this population.

Who can enroll

The trial aims to recruit approximately 400 individuals over age 12 with newly diagnosed grade 3 astrocytoma at cancer centers across the United States. The focus on newly diagnosed patients means the study will test vorasidenib as part of initial treatment rather than as salvage therapy after recurrence.

What we don't know yet

This is a trial launch, not a result. The efficacy and safety of combining vorasidenib with temozolomide in this setting remain unproven. IDH inhibitors have shown activity in lower-grade, slower-growing IDH-mutant tumors, but grade 3 astrocytomas are more aggressive, and it's an open question whether the same mechanism will produce clinically meaningful benefits in this context.

The combination may introduce new toxicities. Temozolomide already suppresses bone marrow and can cause nausea, fatigue, and other side effects. Adding a second agent increases the potential for adverse events, and the trial will need to determine whether the combination is tolerable enough for sustained use.

Recruitment of 400 patients across US cancer centers for a relatively rare brain tumor subtype may take years, and final results are likely several years beyond enrollment completion.

The broader IDH targeting landscape

Vorasidenib is part of a growing wave of IDH-targeted therapies being tested across multiple brain tumor types and grades. The Alliance trial is notable for testing the drug in combination with standard chemotherapy in the frontline setting - a high-stakes bet that blocking the driving mutation from the beginning of treatment could change the trajectory of the disease.

For patients with grade 3 IDH-mutant astrocytoma, the current standard of care offers real benefit but not a cure. Most tumors eventually progress. If vorasidenib can extend the interval before recurrence - or prevent it entirely in some patients - it would represent a meaningful advance in a disease where treatment options have remained largely static.